公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2014 | Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer | YEN-TING LIN ; YU-FEN WANG ; CHIH-HSIN YANG ; CHONG-JEN YU ; SHANG-GIN WU ; JIN-YUAN SHIH ; PAN-CHYR YANG | Journal of Thoracic Oncology | 49 | 38 | |
2013 | Diarrhea associated with afatinib: An oral ErbB family blocker | CHIH-HSIN YANG ; Reguart N; Barinoff J; Köhler J; Uttenreuther-Fischer M; Stammberger U; O'Brien D; Wolf J; Cohen E.E. | Expert Review of Anticancer Therapy | 91 | 86 | |
2004 | Differential effects of carboxyfullerene on MPP+/MPTP-induced neurotoxicity | Lin A.M.Y; CHIH-HSIN YANG ; Ueng Y.-F; Luh T.Y; Liu T.Y; Lay Y.P; Ho L.T. | Neurochemistry International | 28 | 27 | |
2005 | Docetaxel-induced recall dermatitis on previous laser treatment sites [2] | CHIA-YU CHU ; CHIH-HSIN YANG | British Journal of Dermatology | 6 | 5 | |
2018 | Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) | Wu Y.-L; Hirsh V; Sequist L.V; Hu C.-P; Feng J; Lu S; Huang Y; Schuler M; Mok T; Yamamoto N; O’Byrne K; Geater S.L; Zhou C; Massey D; Märten A; Lungershausen J; CHIH-HSIN YANG | Patient | 20 | 17 | |
2018 | Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion | SHANG-GIN WU ; Liu Y.-N.; CHONG-JEN YU ; CHIH-HSIN YANG ; JIN-YUAN SHIH | Genes Chromosomes and Cancer | 10 | 10 | |
2018 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study | Garassino M.C; Cho B.-C; Kim J.-H; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray J.E; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo R.A; Huang Y; Wadsworth C; Dennis P.A; Rizvi N.A; Paz-Ares Rodriguez L; Novello S; Hiret S; Schmid P; Laack E; Califano R; Maemondo M; Kim S.-W; Chaft J; Vicente Baz D; Berghmans T; Kim D.-W; Surmont V; Reck M; Han J.-Y; Holgado Martin E; Belda Iniesta C; Oe Y; Chella A; Chopra A; Robinet G; Soto Parra H; Thomas M; Cheema P; Katakami N; Su W.-C; Kim Y.-C; Wolf J; Lee J.-S; Saka H; Milella M; Ramos Garcia I; Sibille A; Yokoi T; Kang E.J; Atagi S; Spaeth-Schwalbe E; Nishio M; Imamura F; Gabrail N; Veillon R; Derijcke S; Maeda T; Zylla D; Kubiak K; Santoro A; Uy M.N; Lucien Geater S; Italiano A; Kowalski D; Barlesi F; Chen Y.-M; Spigel D; Chewaskulyong B; Garcia Gomez R; Alvarez Alvarez R; CHIH-HSIN YANG ; Hsia T.-C; Denis F; Sakai H; Vincent M; Goto K; Bosch-Barrera J; Weiss G; Canon J.-L; Scholz C; Aglietta M; Kemmotsu H; Azuma K; Bradbury P; Feld R; Chachoua A; Jassem J; Juergens R; Palmero Sanchez R; Malcolm A; Vrindavanam N; Kubota K; Waller C; Waterhouse D; Coudert B; Mark Z; Satouchi M; Chang G.-C; Herzmann C; Chaudhry A; Giridharan S; Hesketh P; Ikeda N; Boccia R; Iannotti N; Haigentz M; Reynolds J; Querol J; Nakagawa K; Sugawara S; Tan E.H; Hirashima T; Gettinger S; Kato T; Takeda K; Juan Vidal O; Mohn-Staudner A; Panwalkar A; Daniel D; Kobayashi K; Ladrera G.E.I; Schulte C; Sebastian M; Cernovska M; Coupkova H; Havel L; Pauk N; Singh J; Murakami S; Csoszi T; Losonczy G; Price A; Anderson I; Iqbal M; Torri V; Juhasz E; Khanani S; Koubkova L; Levy B; Page R; Bocskei C; Crinò L; Einspahr D; Hagenstad C; Juat N; Overton L; Garrison M; Szalai Z; ATLANTIC Investigators | The Lancet Oncology | 468 | 397 | |
2012 | Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin | YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHUNG-MING CHEN ; Hu F.-C.; Hsu H.-H.; WEN-YIH TSENG ; TIFFANY TING-FANG SHIH ; PAN-CHYR YANG ; Chih-Hsin CHIH-HSIN YANG | Journal of Magnetic Resonance Imaging | 52 | 43 | |
2016 | Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials | CHIH-HSIN YANG ; Sequist L.V; Zhou C; Schuler M; Geater S.L; Mok T; Hu C.-P; Yamamoto N; Feng J; O'Byrne K; Lu S; Hirsh V; Huang Y; Sebastian M; Okamoto I; Dickgreber N; Shah R; Märten A; Massey D; Wind S; Wu Y.-L. | Annals of Oncology | 152 | 142 | |
2022 | The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX) | Bang, Tami J; Hu, Junxiao; Patil, Tejas; Barón, Anna E; Gao, Dexiang; CHIH-HSIN YANG ; HUNG-YANG KUO ; HSIN-CHIEH HUANG ; Sachs, Peter B; Camidge, D Ross | Clinical lung cancer | 0 | 0 | |
2018 | The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib | Vishwanathan K; Dickinson P.A; So K; Thomas K; Chen Y.-M; De Castro Carpeño J; Dingemans A.-M.C; Kim H.R; Kim J.-H; Krebs M.G; Chih-Hsin CHIH-HSIN YANG ; Bui K; Weilert D; Harvey R.D. | British Journal of Clinical Pharmacology | 45 | 42 | |
2020 | The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation | SHANG-GIN WU ; CHONG-JEN YU ; CHIH-HSIN YANG ; JIN-YUAN SHIH | Therapeutic Advances in Medical Oncology | 16 | 15 | |
2011 | Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer | Wu J.-Y.; CHONG-JEN YU ; YEUN-CHUNG CHANG ; CHIH-HSIN YANG ; JIN-YUAN SHIH ; PAN-CHYR YANG | Clinical Cancer Research | 412 | 364 | |
2023 | Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors | DE-RUI HUANG ; BIN-CHI LIAO ; Hsu, Wei-Hsun; CHING-YAO YANG ; YEN-TING LIN ; SHANG-GIN WU ; TZU-HSIU TSAI ; KUAN-YU CHEN ; CHAO-CHI HO ; WEI-YU LIAO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG ; ANN-LII CHENG ; YING-CHUN SHEN | Oncology | | | |
2017 | Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC | Wu Y.-L; Saijo N; Thongprasert S; CHIH-HSIN YANG ; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang J.-J; Mok T.S.K; Young H; Haddad V; Rukazenkov Y; Fukuoka M. | Lung Cancer | 48 | 38 | |
2022 | Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study | Ahn, Myung J; Kim, Hye R; CHIH-HSIN YANG ; Han, Ji-Yu; Li, Jacky Yu-Chung; Hochmair, Maximilian J; Chang, Gee-Chen; Delmonte, Angelo; Lee, Ki H; Campelo, Rosario G; Gridelli, Cesare; Spira, Alexander I; Califano, Raffaele; Griesinger, Frank; Ghosh, Sharmistha; Felip, Enriqueta; Kim, Dong-Wan; Liu, Yuyin; Zhang, Pingkuan; Popat, Sanjay; Camidge, D Ross | Clinical lung cancer | 5 | 4 | |
2010 | Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in east asian patients with advanced non-small cell lung cancer: Results of an exploratory subgroup analysis of a phase III trial | CHIH-HSIN YANG ; Simms L; Park K; Lee J.S; Scagliotti G; Orlando M. | Journal of Thoracic Oncology | 50 | 43 | |
2022 | Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer | Jänne P.A.; Baik C.; Su W.-C.; Johnson M.L.; Hayashi H.; Nishio M.; Kim D.-W.; Koczywas M.; Gold K.A.; Steuer C.E.; Murakami H.; CHIH-HSIN YANG ; Kim S.-W.; Vigliotti M.; Shi R.; Qi Z.; Qiu Y.; Zhao L.; Sternberg D.; Yu C.; Yu H.A. | Cancer discovery | 118 | 85 | |
2021 | Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study | CHIH-HSIN YANG ; Reckamp K.L.; Kim Y.-C.; Novello S.; Smit E.F.; Lee J.-S.; Su W.-C.; Akerley W.L.; Blakely C.M.; Groen H.J.M.; Bazhenova L.; Carcereny Costa E.; Chiari R.; Hsia T.-C.; Golsorkhi T.; Despain D.; Shih D.; Popat S.; Wakelee H. | JTO Clinical and Research Reports | 10 | 0 | |
2021 | Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial | CHIH-HSIN YANG ; Mok T.S.K.; Lu S.; Nakagawa K.; Yamamoto N.; Shi Y.-K.; Zhang L.; Soo R.A.; Morita S.; Tamura T. | JTO Clinical and Research Reports | 0 | 0 | |